Literature DB >> 23594123

Can you vaccinate against substance abuse?

Thomas R Kosten1, Coreen B Domingo.   

Abstract

Vaccines are being developed against substance abuse and most progress has been made with anti-cocaine, nicotine and opiate vaccines, but new ones are being developed for methamphetamine and may be in humans within 18 - 24 months. These haptenated vaccines share a common problem in that only about one-third of those vaccinated get a sufficiently robust antibody titer to enable them to effectively block drug use. This problem is being addressed with better carrier proteins and new adjuvants beyond alum. This review provides details about these developing vaccines that act through pharmacokinetic rather than pharmacodynamics blockade. Due to this pharmacokinetic mechanism of keeping abused drugs in the bloodstream and not allowing them entry into the brain or other organs, these vaccines have very few side effects compared to other blockers used in addictions treatment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23594123      PMCID: PMC4154471          DOI: 10.1517/14712598.2013.791278

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN: 1471-2598            Impact factor:   4.388


  33 in total

Review 1.  Vaccines against morphine/heroin and its use as effective medication for preventing relapse to opiate addictive behaviors.

Authors:  Benito Anton; Alberto Salazar; Anabel Flores; Maura Matus; Rodrigo Marin; Jorge-Alberto Hernandez; Philippe Leff
Journal:  Hum Vaccin       Date:  2009-04-08

Review 2.  A review of opioid dependence treatment: pharmacological and psychosocial interventions to treat opioid addiction.

Authors:  Jennifer C Veilleux; Peter J Colvin; Jennifer Anderson; Catherine York; Adrienne J Heinz
Journal:  Clin Psychol Rev       Date:  2009-10-30

Review 3.  Vaccines against drug abuse.

Authors:  X Y Shen; F M Orson; T R Kosten
Journal:  Clin Pharmacol Ther       Date:  2011-11-30       Impact factor: 6.875

4.  A vaccine strategy that induces protective immunity against heroin.

Authors:  G Neil Stowe; Leandro F Vendruscolo; Scott Edwards; Joel E Schlosburg; Kaushik K Misra; Gery Schulteis; Alexander V Mayorov; Joseph S Zakhari; George F Koob; Kim D Janda
Journal:  J Med Chem       Date:  2011-06-30       Impact factor: 7.446

5.  Pharmacotherapy in the treatment of addiction: methadone.

Authors:  Mary Jeanne Kreek; Lisa Borg; Elizabeth Ducat; Brenda Ray
Journal:  J Addict Dis       Date:  2010-04

Review 6.  Buprenorphine: new treatment of opioid addiction in primary care.

Authors:  Meldon Kahan; Anita Srivastava; Alice Ordean; Sharon Cirone
Journal:  Can Fam Physician       Date:  2011-03       Impact factor: 3.275

Review 7.  Opioid dependence treatment: options in pharmacotherapy.

Authors:  Angela L Stotts; Carrie L Dodrill; Thomas R Kosten
Journal:  Expert Opin Pharmacother       Date:  2009-08       Impact factor: 3.889

8.  Cocaine-specific antibodies blunt the subjective effects of smoked cocaine in humans.

Authors:  Margaret Haney; Erik W Gunderson; Huiping Jiang; Eric D Collins; Richard W Foltin
Journal:  Biol Psychiatry       Date:  2010-01-01       Impact factor: 13.382

9.  Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial.

Authors:  Bridget A Martell; Frank M Orson; James Poling; Ellen Mitchell; Roger D Rossen; Tracie Gardner; Thomas R Kosten
Journal:  Arch Gen Psychiatry       Date:  2009-10

10.  Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic.

Authors:  D K Hatsukami; D E Jorenby; D Gonzales; N A Rigotti; E D Glover; C A Oncken; D P Tashkin; V I Reus; R C Akhavain; R E F Fahim; P D Kessler; M Niknian; M W Kalnik; S I Rennard
Journal:  Clin Pharmacol Ther       Date:  2011-01-26       Impact factor: 6.875

View more
  15 in total

1.  Levamisole-contaminated cocaine: a hairy affair.

Authors:  Tjeerd van der Veer; Ed Pennings; J W Cohen Tervaert; Lindy-Anne Korswagen
Journal:  BMJ Case Rep       Date:  2015-08-26

2.  Efficacy, but not antibody titer or affinity, of a heroin hapten conjugate vaccine correlates with increasing hapten densities on tetanus toxoid, but not on CRM197 carriers.

Authors:  Rashmi Jalah; Oscar B Torres; Alexander V Mayorov; Fuying Li; Joshua F G Antoline; Arthur E Jacobson; Kenner C Rice; Jeffrey R Deschamps; Zoltan Beck; Carl R Alving; Gary R Matyas
Journal:  Bioconjug Chem       Date:  2015-06-05       Impact factor: 4.774

Review 3.  Adjuvants for vaccines to drugs of abuse and addiction.

Authors:  Carl R Alving; Gary R Matyas; Oscar Torres; Rashmi Jalah; Zoltan Beck
Journal:  Vaccine       Date:  2014-08-08       Impact factor: 3.641

Review 4.  Vaccines against drugs of abuse: where are we now?

Authors:  Berma Kinsey
Journal:  Ther Adv Vaccines       Date:  2014-07

Review 5.  Systems-level view of cocaine addiction: the interconnection of the immune and nervous systems.

Authors:  Christina C Marasco; Cody R Goodwin; Danny G Winder; Nicole L Schramm-Sapyta; John A McLean; John P Wikswo
Journal:  Exp Biol Med (Maywood)       Date:  2014-06-05

6.  Effective active vaccination against methamphetamine in female rats.

Authors:  J D Nguyen; P T Bremer; C S Hwang; S A Vandewater; K C Collins; K M Creehan; K D Janda; M A Taffe
Journal:  Drug Alcohol Depend       Date:  2017-04-14       Impact factor: 4.492

Review 7.  Reducing substance use during adolescence: a translational framework for prevention.

Authors:  Jessica J Stanis; Susan L Andersen
Journal:  Psychopharmacology (Berl)       Date:  2014-01-25       Impact factor: 4.530

Review 8.  Psychostimulant addiction treatment.

Authors:  Karran A Phillips; David H Epstein; Kenzie L Preston
Journal:  Neuropharmacology       Date:  2014-04-12       Impact factor: 5.250

Review 9.  The prevention and eradication of smallpox: a commentary on Sloane (1755) 'An account of inoculation'.

Authors:  Robin A Weiss; José Esparza
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-04-19       Impact factor: 6.237

10.  Pharmacokinetics of α-Pyrrolidinovalerophenone in Male Rats with and without Vaccination with an α-Pyrrolidinovalerophenone Vaccine.

Authors:  Samantha McClenahan; Melinda Gunnell; Michael Owens
Journal:  J Pharm Pharm Sci       Date:  2021       Impact factor: 2.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.